Q3136901 (Q3136901): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The finding of anti-Aquaporin-4 AQP4 IgG in the serum of patients with optic neuromyelitis (NMO), demyelinating inflammatory disease of the central nervous system (CNS), has critically improved the diagnosis of this disease and allowed it to be distinguished from multiple sclerosis (MS). A subgroup of patients with this disease and other NMO spectrum demyelinating processes (NMOSD) has recently been found to be seronegative for anti-AQP4 antibod...) |
||||||||||||||
| Property / summary | |||||||||||||||
The finding of anti-Aquaporin-4 AQP4 IgG in the serum of patients with optic neuromyelitis (NMO), demyelinating inflammatory disease of the central nervous system (CNS), has critically improved the diagnosis of this disease and allowed it to be distinguished from multiple sclerosis (MS). A subgroup of patients with this disease and other NMO spectrum demyelinating processes (NMOSD) has recently been found to be seronegative for anti-AQP4 antibodies but have anti-Aquaporin-1 (AQP1) antibodies or to oligodendrocytes (MOG) myelin glycoprotein. The primary objective of our Project is to develop a diagnostic trial for NMOSD, which is highly sensitive, specific and quantitative based on the specific reaction of AQP4, AQP1 and MOG, with the antibodies present in the serum of patients through immunodetection trials in transfected cells that overexpress these proteins. We will follow the evolution over time of these serum antibodies, evaluating their correlation with activity. The etiology of this entity is unknown, considering the participation of genetic and environmental factors possible. In this sense, we intend to analyse its possible genetic component by sequencing and analysing the expression of the AQP4, AQP1 and MOG genes. (English) | |||||||||||||||
| Property / summary: The finding of anti-Aquaporin-4 AQP4 IgG in the serum of patients with optic neuromyelitis (NMO), demyelinating inflammatory disease of the central nervous system (CNS), has critically improved the diagnosis of this disease and allowed it to be distinguished from multiple sclerosis (MS). A subgroup of patients with this disease and other NMO spectrum demyelinating processes (NMOSD) has recently been found to be seronegative for anti-AQP4 antibodies but have anti-Aquaporin-1 (AQP1) antibodies or to oligodendrocytes (MOG) myelin glycoprotein. The primary objective of our Project is to develop a diagnostic trial for NMOSD, which is highly sensitive, specific and quantitative based on the specific reaction of AQP4, AQP1 and MOG, with the antibodies present in the serum of patients through immunodetection trials in transfected cells that overexpress these proteins. We will follow the evolution over time of these serum antibodies, evaluating their correlation with activity. The etiology of this entity is unknown, considering the participation of genetic and environmental factors possible. In this sense, we intend to analyse its possible genetic component by sequencing and analysing the expression of the AQP4, AQP1 and MOG genes. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The finding of anti-Aquaporin-4 AQP4 IgG in the serum of patients with optic neuromyelitis (NMO), demyelinating inflammatory disease of the central nervous system (CNS), has critically improved the diagnosis of this disease and allowed it to be distinguished from multiple sclerosis (MS). A subgroup of patients with this disease and other NMO spectrum demyelinating processes (NMOSD) has recently been found to be seronegative for anti-AQP4 antibodies but have anti-Aquaporin-1 (AQP1) antibodies or to oligodendrocytes (MOG) myelin glycoprotein. The primary objective of our Project is to develop a diagnostic trial for NMOSD, which is highly sensitive, specific and quantitative based on the specific reaction of AQP4, AQP1 and MOG, with the antibodies present in the serum of patients through immunodetection trials in transfected cells that overexpress these proteins. We will follow the evolution over time of these serum antibodies, evaluating their correlation with activity. The etiology of this entity is unknown, considering the participation of genetic and environmental factors possible. In this sense, we intend to analyse its possible genetic component by sequencing and analysing the expression of the AQP4, AQP1 and MOG genes. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 13:40, 12 October 2021
Project Q3136901 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3136901 in Spain |
Statements
35,600.0 Euro
0 references
44,500.0 Euro
0 references
80.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
0 references
37°23'19.07"N, 5°59'43.22"W
0 references
41091
0 references
El hallazgo de IgG anti-Acuaporina-4 AQP4) en el suero de pacientes con Neuromielitis Óptica(NMO), enfermedad inflamatoria desmielinizante del sistema nervioso central(SNC), ha mejorado de manera crítica el diagnóstico de esta enfermedad y ha permitido distinguirla de la Esclerosis múltiple (EM). Recientemente se ha encontrado que un subgrupo de pacientes con esta enfermedad y otros procesos desmielinizantes del espectro de la NMO (NMOsd) resultan seronegativos para anticuerpos anti-AQP4 pero presentan anticuerpos anti-Acuaporina-1 (AQP1) o frente a la glicoproteína de la mielina de los oligodendrocitos(MOG). El objetivo primario de nuestro Proyecto consiste en desarrollar un ensayo de diagnóstico para el NMOsd, de alta sensibilidad, especificidad y que sea cuantitativo basado en la reacción específica de AQP4, AQP1 y MOG, con los anticuerpos presentes en el suero de los pacientes mediante ensayos de inmunodetección en células transfectadas que sobreexpresen estas proteínas. Seguiremos la evolución a lo largo del tiempo de dichos anticuerpos en suero, evaluando su correlación con la actividad. La etiología de esta entidad se desconoce, considerándose posible la participación de factores genéticos y ambientales. En este sentido, pretendemos analizar su posible componente genético mediante la secuenciación y análisis de expresión de los genes AQP4, AQP1 y MOG. (Spanish)
0 references
The finding of anti-Aquaporin-4 AQP4 IgG in the serum of patients with optic neuromyelitis (NMO), demyelinating inflammatory disease of the central nervous system (CNS), has critically improved the diagnosis of this disease and allowed it to be distinguished from multiple sclerosis (MS). A subgroup of patients with this disease and other NMO spectrum demyelinating processes (NMOSD) has recently been found to be seronegative for anti-AQP4 antibodies but have anti-Aquaporin-1 (AQP1) antibodies or to oligodendrocytes (MOG) myelin glycoprotein. The primary objective of our Project is to develop a diagnostic trial for NMOSD, which is highly sensitive, specific and quantitative based on the specific reaction of AQP4, AQP1 and MOG, with the antibodies present in the serum of patients through immunodetection trials in transfected cells that overexpress these proteins. We will follow the evolution over time of these serum antibodies, evaluating their correlation with activity. The etiology of this entity is unknown, considering the participation of genetic and environmental factors possible. In this sense, we intend to analyse its possible genetic component by sequencing and analysing the expression of the AQP4, AQP1 and MOG genes. (English)
12 October 2021
0 references
Sevilla
0 references
Identifiers
PI16_01249
0 references